Table 2. The relationship between inflammatory cell infiltrate and clinicopathological characteristics of patients with primary operable invasive ductal breast cancer.
| No inflammatory cell infiltrate ( n =30) | Inflammatory cell infiltrate ( n =438) | (P-value) | |
|---|---|---|---|
| Age (⩽50/>50 years) | 5/25 | 133/305 | 0.112 |
| Size (⩽20/21–50/>50 mm) | 22/8/0 | 258/166/13 | 0.095 |
| Grade (I/II/III) | 12/14/4 | 82/168/188 | <0.001 |
| Involved lymph node (0/1–3/>3) | 19/7/4 | 234/125/74 | 0.361 |
| Oestrogen-receptor status (ER−/ER+) | 0/29 | 159/254 | <0.001 |
| Progesterone-receptor status (PR−/PR+) | 8/20 | 235/182 | 0.004 |
| HER-2 status (HER-2−/HER-2+) | 25/3 | 345/70 | 0.396 |
| Ki-67 status (low Ki-67/high Ki-67) | 21/5 | 314/99 | 0.582 |
| Vascular invasion (absent/present) | 20/6 | 183/165 | 0.016 |
| % Tumour lymphocyte infiltrate (median, range) | 0 | 98 (0–100) | <0.001 |
| % Tumour plasma cell infiltrate (median, range) | 0 | 1 (0–90) | <0.001 |
| % Other inflammatory cell infiltrate (median, range) | 0 | 0 (0–85) | <0.001 |
| Macrophages (median, range) | 100 (24–221) | 126 (14–619) | 0.348 |
| Loco-regional treatment (Lumpectomy±radiotherapy/mastectomy±radiotherapy) | 12/18 | 167/271 | 0.838 |
| Systemic treatment (ER-based treatment; hormonal/hormonal+chemotherapy/chemotherapy/none) | 20/6/2/2 | 218/86/99/27 | 0.088 |
| Cancer-specific survival (months)a | 134 (109–159) | 152 (147–157) | 0.098 |
Abbreviations: CI=confidence interval; ER=oestrogen receptor; HER-2=human epidermal growth factor receptor-2; PR=progesterone receptor.
a
Mean (95% CI).